NCT Number: NCT00002402
A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines
The purpose of this study is to see if it is safe and effective to give AIDSVAX B/B or AIDSVAX B/E, two potential HIV vaccines, to HIV-negative volunteers.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Dr Frank Judson / Director of Public Health Dept, Denver, Colorado, United States
About this study
Patients are randomized to 1 of the 2 following arms and administered 1 or 2 injections into the deltoid muscle at 0, 1, 6, and 12 months:
Arm A: Patients receive 1 of 3 doses of AIDSVAX B/B vaccine (MN rgp120/HIV-1 plus GNE8 rgp120/HIV-1) in alum adjuvant.
Arm B: Patients receive AIDSVAX B/E (MN rgp120/HIV-1 plus A244 rgp120/HIV-1) vaccine in alum adjuvant.
Patients are evaluated at 1 hr, 3 days, and 14 days after each immunization and at 18 months after the first immunization.
An interim analysis is performed after all patients receive the second dose (at 1 month).
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patients must:
Be HIV-uninfected men and women at low or intermediate risk for HIV-1 infection.
Treatment and study plan
MN rgp120/HIV-1 and A244 rgp120/HIV-1
BiologicalAluminum hydroxide
BiologicalSponsors and collaborators
Lead sponsor
VaxGen
Industry
Registry information
Official study title
Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
NCT05911360
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Phoenix, Arizona, United States
View Trial DetailsStudy of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
NCT00164281
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Gaborone, Botswana
View Trial DetailsEnding the HIV Epidemic Through Point-of-Care Technologies (EHPOC)
NCT04793750
Acquired Immunodeficiency Syndrome, Bacterial Infections
Baltimore, Maryland, United States
View Trial DetailsEfficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)
NCT00113282
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Paris, France
View Trial Details